Key result
Perioperative beta-blockade increased major adverse cardiac events compared to no beta-blockade (6.5% vs 3.0%; RR 2.38; 95% CI 1.43-3.96), particularly when hemoglobin decreased >35%.
Why the study?
Does perioperative beta-blockade increase major adverse cardiac events in noncardiac surgical patients experiencing acute surgical anemia?
Cohort (n=4,387)
Does perioperative beta-blockade increase major adverse cardiac events in noncardiac surgical patients experiencing acute surgical anemia?
Relative Risk: 2.38 (95% CI 1.43–3.96)
Absolute Event Rate: 6.5% vs 3%
p-value: p=0.0009
Perioperative beta-blockade is associated with an increased risk of major adverse cardiac events in noncardiac surgical patients who experience a hemoglobin decrease exceeding 35% of baseline.
Cautions against perioperative beta-blockade in anemic noncardiac surgery patients; leaves open causal confirmation in randomized trials.
BACKGROUND: Despite decreasing cardiac events, perioperative beta-blockade also increases perioperative stroke and mortality. Major bleeding and/or hypotension are independently associated with these outcomes. To investigate the hypothesis that beta-blockade limits the cardiac reserve to compensate for acute surgical anemia, the authors examined the relationship between cardiac events and acute surgical anemia in patients with and without beta-blockade. METHODS: The records of all noncardiac, nontransplant surgical patients between March 2005 and June 2006 were retrospectively retrieved. The primary outcome was a composite that comprised myocardial infarction, nonfatal cardiac arrest, and in-hospital mortality (major adverse cardiac event). The lowest recorded hemoglobin in the first 3 days defined nadir hemoglobin. Propensity scores estimating the probability of receiving a perioperative beta-blocker were used to match (1:1) patients who did or did not receive beta-blockers postoperatively. The relationship between nadir hemoglobin and major adverse cardiac event was then assessed. RESULTS: This analysis identified 4,387 patients in whom nadir hemoglobin could be calculated; 1,153 (26%) patients were administered beta-blockers within the first 24 h of surgery. Propensity scores created 827 matched pairs that were well balanced for all measured confounders. Major adverse cardiac event occurred in 54 (6.5%) beta-blocked patients and in 25 (3.0%) beta-blocker naive patients (relative risk 2.38; 95% CI 1.43-3.96; P = 0.0009). The restricted cubic spline relationship demonstrated that this difference was restricted to those patients in whom the hemoglobin decrease exceeded 35% of the baseline value. CONCLUSIONS: beta-Blocked patients do not seem to tolerate surgical anemia when compared with patients who are naive to beta-blockers. Prospective studies are required to validate these findings.
No takes yet. Share an insight, caveat, or question.
Beattie et al. (2009) conducted a cohort in Noncardiac, nontransplant surgery (n=4,387). Perioperative beta-blockade vs. No beta-blockade (beta-blocker naive) was evaluated on Composite of myocardial infarction, nonfatal cardiac arrest, and in-hospital mortality (major adverse cardiac event) (RR 2.38, 95% CI 1.43-3.96, p=0.0009). Perioperative beta-blockade increased major adverse cardiac events compared to no beta-blockade (6.5% vs 3.0%; RR 2.38; 95% CI 1.43-3.96), particularly when hemoglobin decreased >35%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: